Search

for
Search:

Research

5 / 1000+ results

research Surrogate end-points or primary outcomes in clinical trials in women with polycystic ovary syndrome?

38 citations , June 2004 in “Human Reproduction”

This review discusses the challenges of using surrogate variables versus primary clinical end-points in PCOS trials and reports no new research results; the authors suggest focusing future studies on primary outcomes.

Case-Only Trees and Random Forests for Exploring Genotype-Specific Treatment Effects in Randomized Clinical Trials with Dichotomous End Points

research Case-Only Trees and Random Forests for Exploring Genotype-Specific Treatment Effects in Randomized Clinical Trials with Dichotomous End Points

5 citations , July 2019 in “Applied statistics/Journal of the Royal Statistical Society. Series C, Applied statistics”

In this study, applying case-only trees and random forests to a prostate cancer prevention trial revealed genotypes that may influence the efficacy of finasteride for prostate cancer prevention.

research International PCOS guideline clinical research priorities roadmap: a co-designed approach aligned with end-user priorities in a neglected women’s health condition

15 citations , November 2024 in “EClinicalMedicine”

This abstract does not report specific study results but describes the funding and collaboration involved in developing the International PCOS Guidelines by multiple health research organizations.

research A flexible fixed-sequence testing method for hierarchically ordered correlated multiple endpoints in clinical trials

55 citations , June 2007 in “Journal of Statistical Planning and Inference”

This study introduces an extended approach to the Bonferroni procedure that accounts for correlations among endpoints, aiming to improve test power while maintaining strong control of the family-wise type I error rate in clinical trials.

research Review of selected endpoints in studies evaluating the effectiveness and efficacy of topical finasteride use for androgenetic alopecia

December 2021 in “International Journal of Medicine in Developing Countries”

This review examined existing studies on topical finasteride for androgenetic alopecia and noted inconsistent application of hair evaluation methods, suggesting a need for standardization in future research.

View more "clinical endpoints" in research →

Community Join

5 / 1000+ results

community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

133 upvotes 2 years ago

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

community Eirion Therapeutics Announces Potential Breakthrough Treatment for Hair Loss Based on First-in-Man Clinical Trial Results

in Update 415 upvotes 1 year ago

ET-02, a new hair loss treatment, shows promising results with a 6-fold increase in hair count, potentially outperforming minoxidil by activating stem cells in hair follicles. Further trials are ongoing to confirm its efficacy and safety, with potential market release in the future.

community New study on applying minox right after derma stamp

47 upvotes 1 month ago

Microneedling combined with minoxidil and finasteride improves hair growth in androgenetic alopecia, with effectiveness varying by severity. The study was retracted due to concerns about validity and potential AI-generated content.

community KX-826+Minoxidil Outperforms Minoxidil Alone for AGA Treatment: 30+ New Hairs/cm² (24 Weeks, P=0.0075)

38 upvotes 1 year ago

KX-826 combined with minoxidil significantly increases hair growth compared to minoxidil alone for treating male androgenetic alopecia, with no unexpected safety concerns. Users discuss various hair loss treatments, including KX-826, minoxidil, finasteride, and RU58841, sharing personal experiences and sourcing information.

community KX-826 Phase II Results Just Dropped (Male AGA) – Key Takeaways

15 upvotes 1 year ago

KX-826 Phase II results show that a 0.5% concentration performs better than 1% for treating male pattern baldness. Concerns about receptor upregulation from long-term DHT antagonism were mentioned.

View more "clinical endpoints" in community →

Learn

7 / 801 results

learn Overview

learn Osteopontin

signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss

learn KY19382

Are there clinical studies showing that KY19382 can regrow hair in androgenic alopecia? No clinical studies have proven KY19382 regrows hair in androgenic alopecia.

learn SCUBE3

What do clinical trials say about the safety and effectiveness of SCUBE3 for hair regrowth? No clinical trial of SCUBE3 for hair regrowth has been registered on ClinicalTrials.gov or published, so there is no human safety or effectiveness data. The evidence is limited to one 2022 laboratory and mouse study reporting that SCUBE3 activates hair follicle stem cells through TGF-beta signalling.

learn Follistatin

Are there any clinical studies supporting follistatin as a hair loss treatment? There is no controlled human trial showing follistatin treats hair loss; the published work is mouse and laboratory biology on the activin/follistatin signalling system, plus one small 2011 phase 1 injection study of a combination product, so follistatin remains experimental and unapproved.

learn Tofacitinib

What types of hair loss conditions are most commonly associated with tofacitinib use in clinical settings? Published studies link tofacitinib mainly to alopecia areata and its severe variants — as an off-label drug being studied for them, not as a cause of hair loss. The evidence is mostly small, open-label or retrospective, and relapse after stopping is commonly reported.

learn GT20029

When will GT20029 be commercially available, and are there any clinical trials on its use? GT20029 is not approved or commercially available anywhere and remains investigational. A published 12-week Phase II study in 180 Chinese men reports hair-count gains over placebo, but no long-term or Phase III data exists, so any launch is years away at best.

View more "clinical endpoints" in learn →

Clinics

6 / 500 results

All 500 clinic results →

Experts

— no results

Try a deeper search in experts →